Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

Combining an anti-CD20 antibody with chemotherapy improved outcomes in patients with CLL and coexisting conditions. In this patient population, obinutuzumab was superior to rituximab when each was combined with chlorambucil.